Quick Answer
HALOZYME THERAPEUTICS, INC. reported Stockholders Equity of $48.81 million for fiscal year 2025.
HALOZYME THERAPEUTICS, INC. Stockholders Equity — Annual History
| Fiscal Year | Stockholders Equity | YoY Change |
|---|---|---|
| 2025 | $48.81M | -86.6% |
| 2024 | $363.82M | +334.1% |
| 2023 | $83.81M | -50.6% |
| 2022 | $169.80M | -13.8% |
| 2021 | $196.95M | +30.4% |
| 2020 | $151.05M | +64.6% |
| 2019 | $91.77M | -63.1% |
| 2018 | $248.89M | +19.4% |
| 2017 | $208.37M | +741.5% |
| 2016 | -$32.48M | -175.5% |
| 2015 | $43.00M | +4.0% |
| 2014 | $41.35M | +306.9% |
| 2013 | -$19.99M | -140.9% |
| 2012 | $48.85M | +348.2% |
| 2011 | $10.90M | -46.4% |
| 2010 | $20.35M | +194.8% |
| 2009 | $6.90M | -55.1% |
| 2008 | $15.38M | — |
Quarterly Stockholders Equity
| Quarter Ending | Stockholders Equity | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $503.92M | +11.3% | +51.4% |
| June 30, 2025 | $332.75M | +15.0% | -31.0% |
| March 31, 2025 | $482.27M | +171.2% | +32.6% |
| December 31, 2024 | $363.82M | +334.1% | -19.6% |
| September 30, 2024 | $452.70M | +81.7% | +56.4% |
| June 30, 2024 | $289.42M | +91.6% | +62.8% |
| March 31, 2024 | $177.81M | +170.0% | +112.2% |
| December 31, 2023 | $83.81M | -50.6% | -66.4% |
- HALOZYME THERAPEUTICS, INC. showed a decrease of -86.6% in Stockholders Equity compared to the prior fiscal year.
- Over the 2008–2025 period, HALOZYME THERAPEUTICS, INC.’s stockholders equity has grown by 217.4% (from $15.38 million to $48.81 million).
- The most recent figure is from HALOZYME THERAPEUTICS, INC.’s fiscal year 2025 report (Form 10-K), filed with the SEC on February 17, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: